CellSeed

CellSeed FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of CellSeed (7776.T) as of Oct 27, 2026 is 91.95 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 102.86 % — a change of -10.61% (lower).

FCF Conversion

91.95 %

YoY

-10.61%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of CellSeed is 2025 91.95 % . FCF Conversion Rate (FCF/EBITDA) of CellSeed was 2024 102.86 % . It decreases by -10.61% lower compared to the previous year.

The CellSeed FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-236.62 JPY
Jan 1, 2019
0.08 JPY
Jan 1, 2020
90.70 JPY
Jan 1, 2021
99.48 JPY
Jan 1, 2022
96.57 JPY
Jan 1, 2023
94.63 JPY
Jan 1, 2024
102.86 JPY
Jan 1, 2025
91.95 JPY
The CellSeed FCF Conversion history
YEARFCF ConversionYoY
91.95 %-10.61%
102.86 %+8.70%
94.63 %-2.01%
96.57 %-2.93%
99.48 %+9.68%
90.70 %+120,177.28%
0.08 %-100.03%
-236.62 %-404.10%
77.81 %-7.96%
84.54 %-50.78%
171.78 %+63.89%
104.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

FCF Conversion Rate (FCF/EBITDA) of CellSeed is 91.95 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of CellSeed changed from 102.86 % to 91.95 %, representing a -10.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) CellSeed since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s CellSeed with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CellSeed

All Key Metrics — CellSeed